Abstract：
A prospective investigation to assess the impact of 3 months of treatment with epigallocatechin gallate (EGCG), vitamin D and D-chiro-inositol (DCI) in the treatment of uterine fibroids (UF) with laparoscopic myomectomy as evidenced by surgical outcomes and effect on liver function.
Non-pregnant or lactating women aged between 30 and 40 years were scheduled for laparoscopic myomectomy to treat symptoms or looking to conceive. After enrollment, patients were assigned to either (1) intervention group, assuming a total of 300 mg EGCG, 50 μg vitamin D, and 50 mg DCI divided in 2 pills per day for 3 months, or (2) control group, including untreated women scheduled to undergo laparoscopic myomectomy after 3 months.
91 patients completed the study. The comparison of the surgical outcomes between the intervention (n = 44) and the control (n = 47) groups revealed that the treatment significantly reduces the duration of surgery (41.93 ± 7.56 min vs 56.32 ± 10.63 min, p < 0.001). Moreover, the treatment also reduced blood loss during surgery (149.09 ± 25.40 mL vs 168.41 ± 21.34 mL, p < 0.001), resulting in treated patients having higher Hb levels at discharge 11.27 ± 0.82 mL vs 10.56 ± 0.82 mL, p < 0.01). The surgery induced an increase in AST and in total bilirubin regardless of the assigned group, and the treatment induced no change in liver function.
Our data suggest that EGCG plus vitamin D, and DCI could represent a safe option for women with UF scheduled for laparoscopic myomectomy, improving surgical outcomes without affecting liver functionality.
Non-pregnant or lactating women aged between 30 and 40 years were scheduled for laparoscopic myomectomy to treat symptoms or looking to conceive. After enrollment, patients were assigned to either (1) intervention group, assuming a total of 300 mg EGCG, 50 μg vitamin D, and 50 mg DCI divided in 2 pills per day for 3 months, or (2) control group, including untreated women scheduled to undergo laparoscopic myomectomy after 3 months.
91 patients completed the study. The comparison of the surgical outcomes between the intervention (n = 44) and the control (n = 47) groups revealed that the treatment significantly reduces the duration of surgery (41.93 ± 7.56 min vs 56.32 ± 10.63 min, p < 0.001). Moreover, the treatment also reduced blood loss during surgery (149.09 ± 25.40 mL vs 168.41 ± 21.34 mL, p < 0.001), resulting in treated patients having higher Hb levels at discharge 11.27 ± 0.82 mL vs 10.56 ± 0.82 mL, p < 0.01). The surgery induced an increase in AST and in total bilirubin regardless of the assigned group, and the treatment induced no change in liver function.
Our data suggest that EGCG plus vitamin D, and DCI could represent a safe option for women with UF scheduled for laparoscopic myomectomy, improving surgical outcomes without affecting liver functionality.
摘要：
目的：一项前瞻性研究，以评估表没食子儿茶素没食子酸酯（EGCG）治疗3个月的影响，维生素D和D-chiro-肌醇（DCI）在腹腔镜子宫肌瘤切除术治疗子宫肌瘤（UF）中的应用，手术效果和对肝功能的影响证明了这一点。
方法：年龄在30至40岁之间的非妊娠或哺乳期妇女计划进行腹腔镜子宫肌瘤切除术，以治疗症状或希望怀孕。注册后，患者被分配到(1)干预组，假设总共300毫克EGCG，50μg维生素D,和50毫克DCI分为2粒每天3个月，或（2）对照组，包括计划在3个月后接受腹腔镜子宫肌瘤切除术的未经治疗的妇女。
结果：91名患者完成了研究。干预组（n=44）和对照组（n=47）之间的手术结果比较显示，治疗显着缩短了手术时间（41.93±7.56分钟vs56.32±10.63分钟，p<0.001)。此外，治疗还减少了手术期间的失血量（149.09±25.40mLvs168.41±21.34mL，p<0.001)，导致接受治疗的患者在出院时Hb水平较高11.27±0.82mLvs10.56±0.82mL，p<0.01)。无论分配的组如何，手术都会引起AST和总胆红素的增加。治疗没有引起肝功能的变化。
结论：我们的数据表明EGCG加维生素D，对于计划进行腹腔镜子宫肌瘤切除术的UF女性来说，DCI可能是一种安全的选择，在不影响肝功能的情况下改善手术结果。
方法：年龄在30至40岁之间的非妊娠或哺乳期妇女计划进行腹腔镜子宫肌瘤切除术，以治疗症状或希望怀孕。注册后，患者被分配到(1)干预组，假设总共300毫克EGCG，50μg维生素D,和50毫克DCI分为2粒每天3个月，或（2）对照组，包括计划在3个月后接受腹腔镜子宫肌瘤切除术的未经治疗的妇女。
结果：91名患者完成了研究。干预组（n=44）和对照组（n=47）之间的手术结果比较显示，治疗显着缩短了手术时间（41.93±7.56分钟vs56.32±10.63分钟，p<0.001)。此外，治疗还减少了手术期间的失血量（149.09±25.40mLvs168.41±21.34mL，p<0.001)，导致接受治疗的患者在出院时Hb水平较高11.27±0.82mLvs10.56±0.82mL，p<0.01)。无论分配的组如何，手术都会引起AST和总胆红素的增加。治疗没有引起肝功能的变化。
结论：我们的数据表明EGCG加维生素D，对于计划进行腹腔镜子宫肌瘤切除术的UF女性来说，DCI可能是一种安全的选择，在不影响肝功能的情况下改善手术结果。
